Epidemiology and Burden of Human Metapneumovirus Among Italian Adults in Outpatient and Inpatient Settings, 2014–2025
Influenza and Other Respiratory Viruses · 2025-10 · 19 (10)
DOI: 10.1111/irv.70175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 20.10.2025. Verfasst von Alexander Domnich und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hygiene Unit, San Martino Polyclinic Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy. Hauptthemen laut MEDLINE: Paramyxoviridae Infections, Metapneumovirus, Respiratory Tract Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative 2 Joint Undertaking, GlaxoSmithKline Biologicals SA.
Abstract (Originalsprache)
Background
Human metapneumovirus (hMPV) has been increasingly recognized as a major contributor to respiratory infections in all age groups. Owing to its recent discovery, available data on the burden of hMPV in adults are still scant and heterogeneous. Here, we aimed to explore the epidemiology, symptomatic profile, and mortality related to hMPV among Italian adults.
Methods
We performed an integrated analysis of several community‐based and hospital‐based studies conducted in Genoa (Italy) between 2014 and 2025. Adults aged ≥ 18 years prescribed with ≥ 1 molecular test for hMPV were eligible.
Results
Of 21,580 and 2671 adults included in the hospital‐based and community‐based studies, 376 and 117, respectively, tested positive for hMPV. Seasonal (November to April) hMPV detection rate was 4.4% (95% CI: 3.6%–5.2%) in the community‐based and 2.4% (95% CI: 2.1%–2.6%) in the hospital‐based studies. Most detections occurred during the spring months. Each 1‐year increase in age was associated with a 1.1% increase in the odds of hMPV positivity (adjusted odds ratio [aOR] 1.011; 95% CI: 1.005–1.016). Clinical presentation of hMPV resembled that of the phylogenetically related respiratory syncytial virus. Among hMPV‐positive inpatients, 7.3% (95% CI: 4.3%–11.5%) died during their hospital encounter. In‐hospital mortality was associated with residency in long‐term care facilities (aOR 8.73; 95% CI: 2.63–29.15) and cancer (aOR 4.51; 95% CI: 1.50–14.35). Conclusions hMPV is a common virological finding in outpatient and inpatient adults and is responsible for a measurable burden, especially among the most frail older adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hygiene Unit, San Martino Polyclinic Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy.
- Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
- Interuniversity Research Centre on Influenza and Other Transmissible Infections (CIRI-IT), Genoa, Italy.
ORCID-Profile: Alexander Domnich, Donatella Panatto, Andrea Orsi
Förderung
- Innovative Medicines Initiative 2 Joint Undertaking
- GlaxoSmithKline Biologicals SA
Zitieren
APA
Domnich, A., Panatto, D., Paolozzi, V., Ogliastro, M., Ricucci, V., Icardi, G., & Orsi, A. (2025). Epidemiology and Burden of Human Metapneumovirus Among Italian Adults in Outpatient and Inpatient Settings, 2014–2025. Influenza and Other Respiratory Viruses, 19(10). https://doi.org/10.1111/irv.70175
Vancouver
Domnich A, Panatto D, Paolozzi V, Ogliastro M, Ricucci V, Icardi G, et al. Epidemiology and Burden of Human Metapneumovirus Among Italian Adults in Outpatient and Inpatient Settings, 2014–2025. Influenza and Other Respiratory Viruses. 2025;19(10). doi:10.1111/irv.70175
BibTeX
@article{Domnich2025,
author = {Domnich, Alexander and Panatto, Donatella and Paolozzi, Vincenzo and Ogliastro, Matilde and Ricucci, Valentina and Icardi, Giancarlo and Orsi, Andrea},
title = {Epidemiology and Burden of Human Metapneumovirus Among Italian Adults in Outpatient and Inpatient Settings, 2014–2025},
journal = {Influenza and Other Respiratory Viruses},
year = {2025},
volume = {19},
number = {10},
doi = {10.1111/irv.70175}
}
EUVIMED